相关实验视频

Updated: May 10, 2025

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

帕金森病中的α-synuclein聚合和亡之间的相互作用:一个时空视角

Haoran Xiang^1,2

¹The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.

Frontiers in neuroscience

|April 23, 2025

概括

帕金森病涉及神经元死亡和α-synuclein (α-Syn) 聚合,与亡有关. 向亡可能为帕金森病提供新的治疗策略.

科学领域:

神经科学是一个神经科学.
病理学病理学病理学
细胞生物学细胞生物学

背景情况:

帕金森病 (PD) 是一种神经退行性疾病,其特征是多巴胺基神经元损失和α-synuclein (α-Syn) 聚合.
目前的PD治疗方法可以控制症状,但不能阻止疾病的进展.
死细胞灭绝,一个受调节的细胞死亡途径,越来越多地涉及到PD的病原体.

研究的目的:

提出帕金森病进展的时空模型.
为了阐明α-Syn聚合,线粒体功能障碍,氧化应激,神经炎症和PD中的亡之间的相互作用.
探索PD中向亡的治疗潜力.

主要方法:

关于PD病变的现有文献的综述.
开发一个概念的时空模型,整合关键的病理过程.
对神经元死亡和疾病进展中死细胞灭亡的作用的分析.

主要成果:

拟议的模型强调了α-Syn聚合,线粒体功能障碍,氧化应激,神经炎症和亡的相互联系.
这些综合过程有助于PD的运动和早期非运动症状.
亡被确定为驱动PD中神经元损失的关键机制.

结论:

亡是帕金森病的一个关键,但尚未被充分研究的机制.
了解亡的时空动态,可以深入了解PD的病原和潜在的诊断标记.
抑制亡是一种有希望的帕金森病治疗途径,有可能增强现有的治疗方法.

关键词:

帕金森病是帕金森氏症的一种疾病.这是一种α-synuclein.线粒体功能障碍线粒体功能障碍尸体的死亡和死亡的死亡.神经炎症是一种神经炎症.氧化应激是一种氧化应激.治疗策略治疗策略

更多相关视频

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

相关概念视频

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...